RERobert Evans

Robert Evans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert Evans has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The author’s reply

    by Maxwell Sandberg, Bridget Funk, Robert Evans, Alejandro R. Rodriguez

    Fatima G, et al. Investig Clin Urol. 2026 Nov;67(6):608-611. https://doi.org/10.4111/icu.20260337

  • Open Access

    The Effect of the Area Deprivation Index on Surgical Outcomes for Benign Cystectomy

    by Maxwell Sandberg, David Thole, Randall Bissette, Madeline Sandberg, Dylan Wolff, Lindsay Schwartz, Ethan Weitzman, Gregory Russell, Robert Evans, Alejandro Rodriguez

    Introduction: The impact of socioeconomic status (SES) on surgical outcomes is often underrecognized. Benign cystectomy (BC) for nononcologic bladder disease carries high morbidity but remains understudied. We evaluated the effect of SES on postoperative outcomes and healthcare utilization following BC. Methods: We retrospectively reviewed all BCs performed at our institution from 2012 to 2025. Neighborhood‐level socioeconomic disadvantage was measured using the area deprivation index (ADI; scale 1–10), with higher scores indicating greater deprivation. Patients were stratified into deciles (ADID). ADI reflects area‐level socioeconomic conditions rather than individual‐level characteristics and therefore may not capture patient‐specific socioeconomic factors. Surgical outcomes, emergency department (ED) utilization, and 90‐day readmissions were compared across ADID groups. Results: Among 183 patients, the median ADI was 5 (IQR 4–8). Preoperative comorbidities, urinary diversion type, operative time, length of stay, and in‐hospital complication rates were similar across ADID groups. ED visits and 90‐day readmission rates did not differ by SES ( p > 0.05). On multivariable analysis, Indiana pouch diversion was associated with higher odds of postoperative complications (OR, 4.2; 95% CI, 1.4–12.8; p < 0.05). Both Indiana pouch (OR, 4.1; 95% CI, 1.3–13.1; p < 0.05) and a neobladder (OR, 3.7; 95% CI, 1.4–9.8; p < 0.05) were associated with a greater likelihood of readmission within 90 days of discharge. Conclusions: SES, as measured by ADID, was not significantly associated with outcomes or postoperative healthcare utilization. BC carries high morbidity regardless of SES. These findings warrant prospective validation.

  • Open Access

    Urinary tract infections after benign cystectomy: Incidence, risk factors, pathogens, and resistance patterns

    by Maxwell Sandberg, David Thole, Randall Bissette, Dylan Wolff, Madeline Sandberg, Lindsay Schwartz, Ethan Weitzman, Robert Evans, Alejandro R. Rodriguez

    Sandberg M, et al. Investig Clin Urol. 2026 ;67:e26. https://doi.org/10.4111/icu.20250644


  • Postsurgery Opiate Use Is Significantly Lower in Patients With Interstitial Cystitis/Bladder Pain Syndrome Following Cystectomy With Urinary Diversion

    by Maxwell Sandberg, Wyatt Whitman, Anita Rong, Brian Andres-Robusto, Gopal Badlani, Robert Evans, Stephen J. Walker


  • Safety, tolerability, and efficacy of LiRIS 400 mg in women with interstitial cystitis/bladder pain syndrome with or without Hunner lesions

    by Robert Evans, Alfred Kohan, Robert Moldwin, Daniel Radecki, Till Geib, Kenneth M. Peters

    Aims: Two phase 2 studies were conducted to assess the efficacy and safety of lidocaine‐releasing intravesical system (LiRIS) in patients with interstitial cystitis/bladder pain syndrome (IC/BPS) with (Study 001; NCT02395042) or without, (Study 002; NCT02411110) Hunner lesions (HL).Methods: Both were multicenter, randomized, double‐blind, placebo‐controlled, and enrolled women aged ≥18 years. In Study 001, patients were randomized 2:1:1 to LiRIS 400 mg/LiRIS 400 mg, placebo/LiRIS 400 mg, or placebo/placebo for a continuous 28 (2 × 14)‐day period. In Study 002, patients were randomized 1:1 to LiRIS 400 mg or placebo for a continuous (single treatment) 14‐day period.Results: In total, 59 and 131 patients received treatment in Studies 001 and 002, respectively. There was no statistically significant difference in the primary endpoint, the change from baseline to Week 4 of follow‐up post‐removal in mean daily average bladder numeric rating scale (NRS) pain score in either study (Study 001: placebo/placebo, −1.6; LiRIS/LiRIS, −2.7, p = 0.142; placebo/LiRIS, −2.5, p = 0.319; Study 002: LiRIS −1.2; placebo, −1.5, p = 0.505). There was no statistically significant difference between groups in daily worst NRS pain score, number of micturitions/day or urgency episodes/day. There was no clear trend for reduction in number of HL for LiRIS vs placebo. The frequency of treatment‐emergent adverse events was similar between treatment groups in both studies; most were mild or moderate intensity.Conclusion: These studies did not demonstrate a treatment effect of LiRIS 400 mg compared with placebo, either in patients with IC/BPS with HL, or in those without HL.


  • Open Access

    Pulsed Electromagnetic Field Therapy as a Complementary Alternative for Chronic Pelvic Pain Management in an Interstitial Cystitis/Bladder Pain Syndrome Patient

    by Tyler L. Overholt, Christina Ross, Robert J. Evans, Stephen J. Walker

    Interstitial cystitis/bladder pain syndrome is a chronic pelvic pain condition with no known etiology that affects millions of women and men in the United States. Current management can be aggressive for individuals who are refractory to less invasive options, often resulting in the use of opioid narcotics and/or surgical procedures under general anesthesia, with higher risks and side effects to patients. Pulsed electromagnetic field therapy is a noninvasive therapeutic strategy that is thought to reduce inflammation and pain via alteration of cellular function and microcirculation. This therapy has demonstrated efficacy in management of other chronic pain syndromes including fibromyalgia and chronic low back pain. Herein, we describe a case of pulsed electromagnetic field therapy for management of interstitial cystitis/bladder pain syndrome that resulted in decreases in pelvic pain, burning with bladder filling, and other nonpelvic pain symptoms. This case provides support for a formal clinical trial to evaluate the efficacy of pulsed electromagnetic field therapy for the management of chronic pelvic pain in interstitial cystitis/bladder pain syndrome.


  • Evaluation of Clinical Use and Cost-Effectiveness of a Flexible Cystoscope System with a Disposable Sheath: A Randomized Clinical Trial

    by Joao P. Zambon, Thomas P. Watkins, Ashok Hemal, Robert J. Evans, Jorge Gutierrez-Aceves, Majid Mirzazadeh, Ryan P. Terlecki, Shaun P. Deveshwar, Kshipra Hemal, Gopal H. Badlani

    Flexible cystoscopy is routinely performed as an outpatient procedure. The use of disposable sheaths can increase cystoscope life span and reduce staff costs. The primary end point of this study was to evaluate procedure related discomfort and pain, physician maneuverability, residual bioburden and reprocessing time. The secondary end point was to analyze the cost-effectiveness of a flexible cystoscope with a disposable sheath compared to a standard flexible cystoscope. This randomized clinical trial was performed with women older than 18 years, with intact cognition and 7 days antibiotic-free who were referred to outpatient clinic for cystoscopy. Patients underwent cystoscopy with a standard flexible cystoscope or flexible cystoscope with disposable sheath. Urinalysis and culture were performed before and 14 days after cystoscopy. Patients filled out a pain/discomfort visual analog scale. Physicians filled out a 5-point Likert scale for the elements of ease of insertion, manipulation, optical quality and overall use. Reprocessing time and costs were compared between both cystoscopes. A total of 60 patients were included in the study, comprised of 30 who underwent standard flexible cystoscopy and 30 who underwent flexible cystoscopy with a protective sheath. Patient discomfort/pain was equivalent in both groups. The Likert scores were similar except for ease of insertion, which was higher with protective sheaths (p <0.02). Protective sheaths were associated with lower reprocessing time and costs (p <0.001). The use of protective sheaths effectively reduced procedure and staff related costs without causing any additional patient discomfort or pain. The learning curve of the sheathed scope may explain the difference reported by physicians regarding the ease of insertion.


  • Innovative Intravesical Therapies

    by Austin G. Hester, Robert J. Evans